Q-omics provides the consensus-scored HOXA-AS3 profile across patient tissues and cancer cell-line models. HOXA-AS3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HOXA-AS3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, HOXA-AS3 RNA expression shows 16,704 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, HNSC, and KIRP as cancer lineages where HOXA-AS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXA-AS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXA-AS3 survival associations across molecular data types. HOXA-AS3 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXA-AS3 RNA expression–survival associations across cancer types. High HOXA-AS3 expression shows unfavorable associations in UCEC, READ, LGG, LAML and CESC, but favorable associations in HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HOXA-AS3 RNA expression.
This table summarizes HOXA-AS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXA-AS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXA-AS3 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in HNSC, KIRP and UCEC. The HNSC box plot shows higher HOXA-AS3 RNA expression in tumor versus normal tissue (log2 FC = +0.209, t-test p < 0.001).
This table shows molecular features associated with HOXA-AS3 in patient tissues and cancer cell lines. In patient samples, HOXA-AS3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
